News & Analysis as of

Life Sciences Corporate Financing Investors

Ballard Spahr LLP

Cautious Optimism For Capital Markets

Ballard Spahr LLP on

Life sciences capital markets in 2025 have been a mixed bag—some rays of light peeking through, but still, plenty of clouds for early-stage companies hoping to tap the public markets. After a long IPO drought, 2024 brought a...more

Knobbe Martens

Heading Towards an Optimistic Initial Public Offerings (IPOs) Resurgence in 2025?

Knobbe Martens on

On January 16th, 2025, GT Medical Technologies, announced that it has raised $37 million in Series D financing round. The financing round was led by Evidity Health Capital and joined by Accelmed Partners. Current investors...more

Latham & Watkins LLP

5 Tips for Navigating PIPEs in the European Life Sciences Sector

Latham & Watkins LLP on

The challenging funding environment will likely prompt small- and mid-cap listed life sciences companies to seek financing through private investments in public equity. Small- and mid-cap life sciences companies typically...more

3 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide